These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38266507)
21. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
22. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis. Shimonishi N; Sasai K; Ogiwara K; Furukawa S; Nakajima Y; Mizumachi K; Yada K; Takeyama M; Shima M; Mizuno N; Nogami K Int J Hematol; 2023 Dec; 118(6):690-698. PubMed ID: 37803190 [TBL] [Abstract][Full Text] [Related]
23. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Wang CP; Young G; Thornburg CD Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049 [TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963 [TBL] [Abstract][Full Text] [Related]
25. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557 [TBL] [Abstract][Full Text] [Related]
26. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955 [TBL] [Abstract][Full Text] [Related]
27. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors. Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992 [TBL] [Abstract][Full Text] [Related]
28. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146 [TBL] [Abstract][Full Text] [Related]
29. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761 [TBL] [Abstract][Full Text] [Related]
30. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851 [TBL] [Abstract][Full Text] [Related]
31. Emicizumab: A Review in Haemophilia A. Blair HA Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880 [TBL] [Abstract][Full Text] [Related]
32. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data. Misgav M; Brutman-Barazani T; Budnik I; Avishai E; Schapiro J; Bashari D; Barg AA; Lubetsky A; Livnat T; Kenet G Haemophilia; 2021 Mar; 27(2):253-260. PubMed ID: 33595174 [TBL] [Abstract][Full Text] [Related]
33. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence. Kenet G; Fujii T Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654 [TBL] [Abstract][Full Text] [Related]
34. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study. Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431 [TBL] [Abstract][Full Text] [Related]
35. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A. Agarwal S; Hermans C; Miesbach W; Peyvandi F; Sidonio R; Osmond D; Newman V; Henshaw J; Pipe S Haemophilia; 2024 Jul; 30(4):905-913. PubMed ID: 38684460 [TBL] [Abstract][Full Text] [Related]
36. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559 [TBL] [Abstract][Full Text] [Related]
37. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Ebbert PT; Xavier F; Seaman CD; Ragni MV Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522 [TBL] [Abstract][Full Text] [Related]
38. Acute treatment of intracranial hemorrhage complicated by hemophilia a and emicizumab therapy. Clark K; Patrick BM; Torian SC Am J Emerg Med; 2024 Feb; 76():272.e1-272.e2. PubMed ID: 38123423 [TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413 [TBL] [Abstract][Full Text] [Related]
40. Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature. Swan D; Paran S; Nolan B Haemophilia; 2022 Jan; 28(1):42-45. PubMed ID: 34786787 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]